The 12 most recent market catalysts affecting $KZIA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target
BTIG analyst Kambiz Yazdi has reiterated a 'Buy' rating and maintained a $40 price target for Kazia Therapeutics. This action signals continued confidence from a prominent investme…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40
BTIG analyst Kambiz Yazdi maintained a 'Buy' rating on Kazia Therapeutics and raised the price target from $34 to $40. This action signals increased confidence from a reputable ana…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Kazia Therapeutics Reports New Preclinical And Translational Data Showing Lead Asset Paxalisib Reduced Tumor Burden By 52% In MSS/pMMR Colorectal Cancer
Kazia Therapeutics (KZIA) reported compelling preclinical data for paxalisib, demonstrating a 52% reduction in tumor burden in MSS/pMMR colorectal cancer and further reduction when…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Kazia Therapeutics Announces New Preclinical Data Showing Safety, Anti-Tumor Activity Of Paxalisib In HR+/HER2- Breast Cancer; First Patient Expected By Year-End 2026 And Full Enrollment By End Of 2027
Kazia Therapeutics announced promising preclinical results for paxalisib in a significant breast cancer subtype, HR+/HER2-. The data showed not only safety and anti-tumor activity …
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 75
Kazia Therapeutics Announces Pricing Of $40M Underwritten Offering Of ADSs And Pre-Funded Warrants
Kazia Therapeutics has priced an underwritten public offering of ADSs and pre-funded warrants, aiming to raise $40 million. This capital infusion is critical for a clinical-stage b…
Aug 28, 2026
Corporate Catalyst
Bearish
Impact 85
Kazia Therapeutics shares are trading lower after the company announced pricing of up to $120 million public offering.
The announcement of a public offering, especially one of this size relative to the company's market capitalization, almost invariably leads to a negative reaction in the short term…
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 85
Kazia Therapeutics Prices ~$40M Offering Of 2.58M American Depositary Shares At $17.825 Per ADS
Kazia Therapeutics announced the pricing of a public offering to raise approximately $40 million in gross proceeds, with potential for an additional $80 million if all warrants are…
Aug 27, 2026
Corporate Catalyst
Bearish
Impact 85
Kazia Therapeutics shares are trading lower after the company announced a proposed public offering.
The proposed public offering by Kazia Therapeutics is a direct corporate catalyst, leading to an immediate negative impact on its share price. Public offerings, especially for smal…
Aug 27, 2026
Corporate Catalyst
Neutral
Impact 75
Kazia Therapeutics Commences Offering Of American Depositary Shares; Terms Undisclosed
Kazia Therapeutics is commencing a public offering of ADSs and two series of warrants. This move is a common way for biotechnology companies to raise capital to fund their research…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29
Canaccord Genuity's initiation of coverage on Kazia Therapeutics with a 'Buy' rating and a $29 price target is a significant event for the company. Analyst coverage, especially wit…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 65
Kazia Therapeutics Files Provisional Patent Application Supporting Therapeutic Strategy Designed To Prevent Metastatic Recurrence In Patients With High-Risk Early-Stage Triple-Negative Breast Cancer
Kazia Therapeutics announced the filing of a provisional patent application for a therapeutic strategy involving paxalisib to prevent metastatic recurrence in high-risk early-stage…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target
The filing indicates that BTIG analyst Kambiz Yazdi has reiterated a 'Buy' rating and maintained a $34 price target for Kazia Therapeutics (KZIA). This action signals continued con…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.